Pinetree Therapeutics, a US-based biotech, raised $47 million in Series B funding, surpassing its target, to advance its antibody-based protein degradation therapies and expand global partnerships.
#YonhapInfomax #PinetreeTherapeutics #SeriesBFunding #AntibodyDrugConjugate #AstraZeneca #TargetedProteinDegradation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=87765